Nasrin Shayanfar1, Ali Zare-Mirzaie2, Mahsa Mohammadpour3, Ensieh Jafari4, Amirhosein Mehrtash5, Nikoo Emtiazi6, Fatemeh Tajik7. 1. Department of Pathology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. 2. Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 3. Department of Medical School, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Biology, Faculty of Basic Science, Noor Danesh University, Isfahan, Iran. 5. Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. 6. Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Nikooemtiazi9@gmail.com. 7. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. efateme_tajik@yahoo.com.
Abstract
INTRODUCTION: Recent developments in genomic sequencing have led to the identification of somatic mutations in isocitrate dehydrogenase 1 (IDH1) in various malignancies. IDH1 R132H is the most common mutation of IDH1, which affects codon 132 and results in the conversion of amino acid residue arginine (R) to histidine (H). This study is designed to evaluate the association between the expression of IDH1 R132H and clinicopathological characteristics in laryngeal squamous cell carcinoma (LSCC). METHODS: The expression pattern and clinical significance of IDH1 R132H were investigated in tissue microarrays (TMAs) of 50 LSCC tumors as well as adjacent normal tissues using immunohistochemistry. Then the exons of the 12 tumor samples with negative/weak positive staining were sequenced by applying polymerase chain reaction (PCR). RESULTS: The results demonstrated that the cytoplasmic expression of IDH1 R132H was downregulated in tumor cells compared to adjacent normal tissues. A statistically significant association was found between a low level of cytoplasmic expression of IDH1 R132H protein and an increase in histological grade (p < 0.001), perineural invasion (p = 0.019), and lymph node involvement (p < 0.001). The exon4 sequencing results showed that only one sample was positive for IDH1 R132H mutation. IDH1 R132H expression was observed in 39 (78.0%) LSCC samples. CONCLUSION: These findings indicate that low cytoplasmic expression of IDH1 R132H may have clinical significance in LSCC patients and is associated with more aggressive tumor behavior and progression of the disease, which can help improve potential treatment in patients with LSCC. Further investigations are needed to understand the biological function of IDH1 R132H and larger sample size to confirm our findings.
INTRODUCTION: Recent developments in genomic sequencing have led to the identification of somatic mutations in isocitrate dehydrogenase 1 (IDH1) in various malignancies. IDH1 R132H is the most common mutation of IDH1, which affects codon 132 and results in the conversion of amino acid residue arginine (R) to histidine (H). This study is designed to evaluate the association between the expression of IDH1 R132H and clinicopathological characteristics in laryngeal squamous cell carcinoma (LSCC). METHODS: The expression pattern and clinical significance of IDH1 R132H were investigated in tissue microarrays (TMAs) of 50 LSCC tumors as well as adjacent normal tissues using immunohistochemistry. Then the exons of the 12 tumor samples with negative/weak positive staining were sequenced by applying polymerase chain reaction (PCR). RESULTS: The results demonstrated that the cytoplasmic expression of IDH1 R132H was downregulated in tumor cells compared to adjacent normal tissues. A statistically significant association was found between a low level of cytoplasmic expression of IDH1 R132H protein and an increase in histological grade (p < 0.001), perineural invasion (p = 0.019), and lymph node involvement (p < 0.001). The exon4 sequencing results showed that only one sample was positive for IDH1 R132H mutation. IDH1 R132H expression was observed in 39 (78.0%) LSCC samples. CONCLUSION: These findings indicate that low cytoplasmic expression of IDH1 R132H may have clinical significance in LSCC patients and is associated with more aggressive tumor behavior and progression of the disease, which can help improve potential treatment in patients with LSCC. Further investigations are needed to understand the biological function of IDH1 R132H and larger sample size to confirm our findings.
Authors: Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh Journal: Cell Rep Date: 2017-05-30 Impact factor: 9.423
Authors: Fonnet E Bleeker; Simona Lamba; Sieger Leenstra; Dirk Troost; Theo Hulsebos; W Peter Vandertop; Milo Frattini; Francesca Molinari; Margaret Knowles; Aniello Cerrato; Monica Rodolfo; Aldo Scarpa; Lara Felicioni; Fiamma Buttitta; Sara Malatesta; Antonio Marchetti; Alberto Bardelli Journal: Hum Mutat Date: 2009-01 Impact factor: 4.878
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate Journal: Oncologist Date: 2011-12-16 Impact factor: 5.837